{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-205079","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.876376+00:00","generated_at":"2026-05-14T23:29:39.448811+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Climb Bio reports positive SC formulation data; ITP data June 2026, pMN/SLE Q4 2026","bullets":["Topline Phase 1 SC data: robust B-cell depletion similar to IV; generally safe and well-tolerated.","Fast Track Designation received for primary membranous nephropathy (pMN).","Initial ITP Phase 1b/2a data from low-dose cohort expected June 2026.","Initial pMN Phase 2 and SLE Phase 1b data expected Q4 2026.","Budoprutug is an anti-CD19 mAb targeting B-cell mediated diseases; trials enrolling to plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-205079","json":"https://secwatch.observer/filing/0001193125-26-205079.json","markdown":"https://secwatch.observer/filing/0001193125-26-205079.md","text":"https://secwatch.observer/filing/0001193125-26-205079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526205079/0001193125-26-205079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000119312526205079/d127757d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:29:39.448811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}